Portal de investigação
Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled ( ehac306, 2022)
Data de publicação:
Data Ahead of Print:
Autores da FMUP
Participantes de fora da FMUP
- Zannad, F
- Butler, J
- Filipattos, G
- Ritter, I
- Schüler, E
- Kraus, BJ
- Pocock, SJ
- Anker, SD
- Packer, M
Unidades de investigação
Abstract
In the originally published version of this manuscript, affiliations for several authors were erroneous. The affiliations were given as follows: João Pedro Ferreira1,2*, Faiez Zannad3,4, Javed Butler5, Gerasimos Filipattos6, Ivana Ritter7, Elke Schüler8, Bettina J Kraus7,9,10, Stuart J. Pocock11, Stefan D. Anker12, and Milton Packer13,14 1Université de Lorraine, Inserm, Centre d’Investigations Cliniques Plurithématique 1433, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France; 2Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal; 3Baylor Heart and Vascular Institute Dallas, TX, USA; 4Imperial College, London, UK; 5University of Mississippi Medical Center, Jackson, MS, USA; 6National and Kapodistrian University of Athens School of Medicine, Athens, Greece; 7Boehringer Ingelheim International GmbH, Ingelheim, Germany; 8mainanalytics GmbH, Sulzbach, Germany; 9Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany; 10Comprehensive Heart Failure Centre, University of Würzburg, Würzburg, Germany; 11London School of Hygiene and Tropical Medicine, London, UK; 12Department of Cardiology (CVK) Berlin Institute of Health Center for Regenerative Therapies (BCRT) German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany; 13Baylor Heart and Vascular Institute Dallas, TX, USA; and 14Imperial College, London, UK The affiliations have now been updated. © The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology.
Dados da publicação
- ISSN/ISSNe:
- 1522-9645, 0195-668X
- Tipo:
- Correction
- Páginas:
- 4377-4377
- Link para outro recurso:
- www.scopus.com
European Heart Journal Oxford University Press
Documentos
- Não há documentos
Filiações
Keywords
- erratum
Proyectos asociados
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022
Citar a publicação
Ferreira JP,Zannad F,Butler J,Filipattos G,Ritter I,Schüler E,Kraus BJ,Pocock SJ,Anker SD,Packer M. Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled ( ehac306, 2022). Eur. Heart J. 2022. 43(41):p. 4377-4377. IF:39,300. (1).
